Braveheart Bio (BRVE) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xencor is the larger company by market cap ($1.83 billion vs $1.80 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | XNCR |
|---|---|---|
| Share price | $20.02 | $24.63 |
| Market cap | $1.80B | $1.83B |
| 1-day change | +4.87% | +0.53% |
| YTD return | — | +60.03% |
| 1-year return | — | +97.58% |
| 5-year return | — | -36.31% |
| EPS (TTM) | $-6.08 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $125.58M |
| Revenue growth (YoY) | — | +13.65% |
| Net income (latest FY) | — | $-91.92M |
| Operating margin | — | -141.35% |
| Net margin | — | -73.20% |
| 52-week high | $32.00 | $30.61 |
| 52-week low | $17.86 | $10.38 |
| Distance from 52-week high | -37.44% | -19.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +126.02% | +27.57% |
| Average volume | 558.38K | 1.32M |
| Shares outstanding | 90.04M | 74.35M |
| Employees | 49 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
BRVE vs XNCR FAQ
Which is bigger, Braveheart Bio or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $1.83B compared with $1.80B for Braveheart Bio (BRVE).
Are Braveheart Bio and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.